Table 2.
Univariate analyses in search of association of bone marrow biopsy outcome and treatment benefit with tumor and prior treatment characteristics
| BMB: tumor infiltration, no./total (%) |
BMB: No tumor infiltration, no./total (%) |
p value* |
Treatment benefit, no./total (%) |
No treatment benefit, no./total (%) |
p value * |
Patients with no available data, no. |
|
|---|---|---|---|---|---|---|---|
| >20 bone lesions | 28/32 (88) | 15/28 (54) | 0.004 | 25/38 (66) | 18/22 (88) | 0.2 | 0 |
| Metastases in lymph nodes | 10/32 (31) | 10/28 (36) | 0.8 | 14/38 (37) | 6/22 (27) | 0.4 | 0 |
| Visceral metastases | 5/32 (16) | 2/28(7) | 0.4 | 4/38 (11) | 3/22 (14) | 1 | 0 |
| Gleason score ≥8 | 21/29 (72) | 15/24 (63) | 0.6 | 20/31 (65) | 16/22 (73) | 0.2 | 7 |
| Metastatic at diagnosis | 7/31 (23) | 12/27 (44) | 0.06 | 14/36 (42) | 5/22 (23) | 0.1 | 2 |
| Treatment of primary with RPS or/and RT | 24/32 (75) | 15/28 (55) | 0.1 | 21/38 (55) | 18/22 (82) | 0.05 | 0 |
| Prior chemotherapy | 26/32 (81) | 22/28 (79) | 1 | 27/38 (71) | 21/22 (95) | 0.041 | 0 |
| Prior chemotherapy >1 line | 10/32 (31) | 6/28 (21) | 0.6 | 8/38 (21) | 8/22 (36) | 0.06 | 0 |
| Prior ketoconazole | 7/32 (22) | 14/28 (50) | 0.03 | 15/38 (39) | 6/22 (27) | 0.8 | 0 |
| Prior multiple hormonal manipulations** | 14/32 (44) | 20/28 (71) | 0.04 | 24/38 (63) | 10/22 (45) | 0.8 | 0 |
| Time to CRPC >1 yr | 21/31 (68) | 18/26 (69) | 1 | 25/37 (68) | 14/20 (70) | 1 | 3 |
| Time to CRPC >2 yr | 17/31 (55) | 11/26 (42) | 0.4 | 18/37 (49) | 10/20 (50) | 0.8 | 3 |
BMB = bone marrow biopsy;; CRPC = castration-resistant prostate cancer; RT = radiation therapy.
*
Fisher exact test.
**
Beyond luteinizing hormone-releasing hormone agonist/antagonist and bicalutamide.